Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Bladder cancer

Validating the EORTC risk tables in BCG-treated patients

Nature Reviews Urology volume 8, pages 480–481 (2011)Cite this article

Subjects

The European Organisation for Research and Treatment of Cancer (EORTC) tables estimate risks of tumor recurrence and progression in patients following transurethral resection of non-muscle-invasive bladder cancer. But how well do the predictive accuracy and discriminative ability of the tables stand up in patients administered bacillus Calmette–Guérin (BCG)?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2,596 patients from seven EORTC trials. Eur. Urol. 49, 466–477 (2006).

    Article  PubMed  Google Scholar 

  2. Hall, M. C. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 178, 2314–2330 (2007).

    Article  PubMed  Google Scholar 

  3. Fernandez-Gomez, J. et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus-Calmette–Guérin: external validation of EORTC risk tables. Eur. Urol. 60, 423–430 (2011).

    Article  PubMed  Google Scholar 

  4. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277–300 (2010).

    Article  PubMed  Google Scholar 

  5. Lamm, D. et al. Updated concepts and treatment of carcinoma in situ. Urol. Oncol. 4, 130–138 (1998).

    Article  CAS  PubMed  Google Scholar 

  6. Shariat, S. F. et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J. Urol. 173, 1518–1525 (2005).

    Article  CAS  PubMed  Google Scholar 

  7. Iasonos, A., Schrag, D., Raj, G. V. & Panageas, K. S. How to build and interpret a nomogram for cancer prognosis. J. Clin. Oncol. 26, 1364–1370 (2008).

    Article  PubMed  Google Scholar 

  8. Lamm, D. L. et al. Maintenance bacillus Calmette–Guérin immunotherapy for recurrent Ta, T1, and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163, 1124–1129 (2000).

    Article  CAS  PubMed  Google Scholar 

  9. Guevara, A. et al. The role of tumor-free status in repeat resection before intravesical bacillus Calmette–Guérin for high grade Ta, T1 and CIS bladder cancer. J. Urol. 6, 2161–2164 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, 33612, FL, USA

    David D. Buethe & Wade J. Sexton

Authors
  1. David D. Buethe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wade J. Sexton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wade J. Sexton.

Ethics declarations

Competing interests

W. J. Sexton has received speakers bureau (honoraria) and grant/research support from Endo Pharmaceuticals. D. D. Buethe declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buethe, D., Sexton, W. Validating the EORTC risk tables in BCG-treated patients. Nat Rev Urol 8, 480–481 (2011). https://doi.org/10.1038/nrurol.2011.118

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2011.118

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing